Marshall Wace, LLP Centessa Pharmaceuticals PLC Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 139,732 shares of CNTA stock, worth $2.46 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139,732
Previous 180,853
22.74%
Holding current value
$2.46 Million
Previous $2.89 Million
19.06%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CNTA
# of Institutions
107Shares Held
119MCall Options Held
5.9KPut Options Held
53K-
Medicxi Ventures Management (Jersey) LTD20MShares$352 Million73.44% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$176 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$171 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.28MShares$111 Million2.62% of portfolio
-
First Light Asset Management, LLC Edina, MN5.94MShares$105 Million8.27% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.66B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...